First Day Healthy Immune Response
On sale on the US market (according to the DSLD)
NaturesPlus AgeLoss, food supplement from the US market
First Day Healthy Immune Response (NaturesPlus AgeLoss), a food supplement au code-barres 097467080034, is described by its US market label. If sold in France, it would be subject to 3 points of French or European regulation, detailed below. Doses of vitamine A are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- Dose déclarée au-delà d'une limite
Sélénium: up to 70 µg a day according to the label (at most 1 serving a day), above the maximum dose of 50 µg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/2340).
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- NaturesPlus AgeLoss
- Barcode
- 097467080034
- Form
- Tablet
- One serving
- 3 tablets
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- Microcrystalline Cellulose, Vegetable Cellulose, Stearic Acid, Magnesium Stearate, Di-Calcium Phosphate, Silica, organic Annatto, organic Amla, organic Guava, organic Rice Protein, Pharmaceutical Glaze
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Vitamin A | Vitamin | 1,500 µg RE (retinol equivalent) |
| Vitamin C | Vitamin | 60 mg |
| Vitamin E | Vitamin | 20 mg |
| Zinc | Mineral | 15 mg |
| Selenium | Mineral | 70 µg |
| First Day Healthy Inflammation Response Blend | Blend | 527 mg |
| Green Tea (Camellia sinensis) | Plant | 100 mg |
| Acai std. concentrate (Euterpe oleracea) | Plant | 100 mg |
| Turmeric (Curcuma longa) | Plant | 75 mg |
| Rhodiola rosea extract | Plant | 50 mg |
| Grape extract | Plant | 50 mg |
| Flamxyl Live Enzyme Matrix | Blend | 90 mg |
| Serrapeptase | Enzyme | 40 mg |
| Coenzyme Q10 | Other substance | 40 mg |
| Bromyl-7 Glycosylated Bromelain Enzyme Complex | Blend | 10 mg |
| Bromelain | Enzyme | not stated |
| Ananain | Enzyme | not stated |
| Comosain | Enzyme | not stated |
| Glycoproteins | Protein | not stated |
| Peroxidase | Enzyme | not stated |
| Phosphatase | Enzyme | not stated |
| Cellulase | Enzyme | not stated |
| Olive leaf/fruit extract | Plant | 60 mg |
| Thione Complex Proprietary Blend | Blend | 2 mg |
| Glutathione | Other substance | not stated |
| Selenium | Mineral | not stated |
| N-Acetyl-Cysteine | Other substance | not stated |
| Grape seed extract | Plant | not stated |
| Origanox | Plant | 150 mg |
| Rejuvabolic Full Spectrum Antioxidant Blend | Blend | 150 mg |
| wild Blueberry | Plant | not stated |
| Quercetin | Other substance | not stated |
| Trans-Resveratrol | Other substance | not stated |
| wild Bilberry | Plant | not stated |
| Cranberry | Plant | not stated |
| Tart Cherry | Plant | not stated |
| Prune (Prunus domestica) | Plant | not stated |
| Raspberry | Plant | not stated |
| Strawberry | Plant | not stated |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: First Day Healthy Inflammation Response
Entered into DSLD on 25 April 2019. Withdrawn from the US market on 17 March 2021 (according to the DSLD).- Different unit, without conversion : Vitamin A: 5,000 IU in this version; 1,500 mcg RAE on the displayed label
- Different unit, without conversion : Vitamin E: 30 IU in this version; 20 mg on the displayed label
Official label: First Day Healthy Inflammation Response
Entered into DSLD on 25 August 2015. Withdrawn from the US market on 11 June 2018 (according to the DSLD).- Active ingredient added : Grape (50 mg)
- Active ingredient added : Micronized Sierra Mountains Trace Minerals (30 mg)
- Active ingredient added : Rhodiola rosea (50 mg)
- Active ingredient removed : Ananain (quantity not stated)
- Active ingredient removed : Bromelain (quantity not stated)
- Active ingredient removed : Cellulase (quantity not stated)
- Active ingredient removed : Comosain (quantity not stated)
- Active ingredient removed : Glycoproteins (quantity not stated)
- Active ingredient removed : Grape extract (50 mg)
- Active ingredient removed : Peroxidase (quantity not stated)
- Active ingredient removed : Phosphatase (quantity not stated)
- Active ingredient removed : Rhodiola rosea extract (50 mg)
- Same quantity, different name: Olive in this version; Olive leaf/fruit extract on the displayed label (60 mg)
- Same quantity, different name: Thione Complex in this version; Thione Complex Proprietary Blend on the displayed label (2 mg)
- Different quantity per serving : FIRST DAY(TM) Healthy Inflammation Response Blend: 554 mg in this version; 527 mg on the displayed label
- Different unit, without conversion : Vitamin A: 5,000 IU in this version; 1,500 mcg RAE on the displayed label
- Different unit, without conversion : Vitamin E: 30 IU in this version; 20 mg on the displayed label
Official label: First Day Healthy Inflammation Response
Entered into DSLD on 25 March 2013. Withdrawn from the US market on 31 July 2015 (according to the DSLD).- Active ingredient added : Grape (50 mg)
- Active ingredient added : Micronized Sierra Mountains Trace Minerals (30 mg)
- Active ingredient added : Rhodiola rosea (50 mg)
- Active ingredient removed : Ananain (quantity not stated)
- Active ingredient removed : Bromelain (quantity not stated)
- Active ingredient removed : Cellulase (quantity not stated)
- Active ingredient removed : Comosain (quantity not stated)
- Active ingredient removed : Cranberry (quantity not stated)
- Active ingredient removed : Glutathione (quantity not stated)
- Active ingredient removed : Glycoproteins (quantity not stated)
- Active ingredient removed : Grape extract (50 mg)
- Active ingredient removed : Grape seed extract (quantity not stated)
- Active ingredient removed : Grape seed extract (quantity not stated)
- Active ingredient removed : N-Acetyl-Cysteine (quantity not stated)
- Active ingredient removed : Peroxidase (quantity not stated)
- Active ingredient removed : Phosphatase (quantity not stated)
- Active ingredient removed : Prune (quantity not stated)
- Active ingredient removed : Quercetin (quantity not stated)
- Active ingredient removed : Raspberry (quantity not stated)
- Active ingredient removed : Rhodiola rosea extract (50 mg)
- Active ingredient removed : Selenium (quantity not stated)
- Active ingredient removed : Strawberry (quantity not stated)
- Active ingredient removed : Tart Cherry (quantity not stated)
- Active ingredient removed : Trans-Resveratrol (quantity not stated)
- Active ingredient removed : wild Bilberry (quantity not stated)
- Active ingredient removed : wild Blueberry (quantity not stated)
- Same quantity, different name: Olive in this version; Olive leaf/fruit extract on the displayed label (60 mg)
- Same quantity, different name: Thione Complex(TM) in this version; Thione Complex Proprietary Blend on the displayed label (2 mg)
- Different quantity per serving : FIRST DAY(TM) Healthy Inflammation Response Blend: 554 mg in this version; 527 mg on the displayed label
- Different unit, without conversion : Vitamin A: 5,000 IU in this version; 1,500 mcg RAE on the displayed label
- Different unit, without conversion : Vitamin E: 30 IU in this version; 20 mg on the displayed label
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Acai std. concentrate
Read the warning, when it applies and the studies cited
ACAI – EUTERPE OLERACEA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (derMarderosian and Beutler 2008).
Sources cited by Health Canada (1)
- derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (derMarderosian and Beutler 2008).
Sources cited by Health Canada (1)
- derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.
- Turmeric
Read the warning, when it applies and the studies cited
TURMERIC - CURCUMA LONGA - Oral
Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000)
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).
Sources cited by Health Canada (2)
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).
Sources cited by Health Canada (6)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).
Sources cited by Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).
Sources cited by Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Condition of application: All uses except for Source of antioxidants and Hepatoprotectant.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 26 September 2025
Turmeric -CURCUMA LONGA - Topical
Cautions and warnings
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Contraindications
Do not use on deep or puncture wounds, animal bites or serious burns.
- Serrapeptase
Read the warning, when it applies and the studies cited
SERRAPEPTASE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gastrointestinal lesions/ulcers, a kidney or liver disorder, or are having surgery (Bhagat et al. 2013; Chopra et al. 2009; Al- Khateeb and Nusair 2008; Mazzone et al. 1990).
Sources cited by Health Canada (4)
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
- Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
- Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial
- Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or anti-inflammatory medications (Bhagat et al. 2013; Chopra et al. 2009; Al-Khateeb and Nusair 2008; Mazzone et al. 1990).
Sources cited by Health Canada (4)
- Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
- Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
- Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial
Known adverse reactions
Stop use if rash, difficulty breathing, hypersensitivity and/or severe allergy occur (Bhagat et al. 2013; Balagi 2007).
Sources cited by Health Canada (1)
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Coenzyme Q10
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : NaturesPlus AgeLoss
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “First Day Healthy Immune Response (NaturesPlus AgeLoss): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/97467080034-first-day-healthy-immune-response-naturesplus-ageloss, updated 23 June 2021.